adalimumab-afzb (Abrilada) vs adalimumab-ryvk (Simlandi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
NCT02480153 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)
Result source: NCT02480153
adalimumab-ryvk (Simlandi)
Marketed by Alvotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | adalimumab-ryvk (Simlandi) |
|---|---|---|
| ACR20 | 68.3% vs 71.3%vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| ACR50 | 62.9% vs 55.6%vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| ACR70 | 36.4% vs 31.9%vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | -0.7 vs -0.7vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-afzb (Abrilada)
- 68.3% vs 71.3%vs Adalimumab-EUNCT02480153
11 other results
- 82.7% vs 79.3% NCT02480153
- 82.3% vs 78.5% NCT02480153
- 83.4% vs 77.8% NCT02480153
- 86.6% vs 82.2% NCT02480153
- 83.5% vs 78% NCT02480153
- 86.6% vs 84.4% NCT02480153
- 78.1% vs 73.7% NCT02480153
- 69.4% vs 68% NCT02480153
- 61.3% vs 59.7% NCT02480153
- 51.9% vs 52.3% NCT02480153
- 31.3% vs 32% NCT02480153
- adalimumab-ryvk (Simlandi)
- —Not reported
ACR50
- adalimumab-afzb (Abrilada)
- 62.9% vs 55.6%vs Adalimumab-EUNCT02480153
11 other results
- 64.3% vs 49.6% NCT02480153
- 61.1% vs 51.9% NCT02480153
- 59.7% vs 49.6% NCT02480153
- 59.6% vs 54.7% NCT02480153
- 61.8% vs 56.3% NCT02480153
- 45.1% vs 47% NCT02480153
- 39.7% vs 39.7% NCT02480153
- 34% vs 33.3% NCT02480153
- 27.6% vs 27.3% NCT02480153
- 17.8% vs 14.3% NCT02480153
- 8.4% vs 6% NCT02480153
- adalimumab-ryvk (Simlandi)
- —Not reported
ACR70
- adalimumab-afzb (Abrilada)
- 36.4% vs 31.9%vs Adalimumab-EUNCT02480153
11 other results
- 38.5% vs 32.6% NCT02480153
- 36% vs 26.7% NCT02480153
- 33.9% vs 30.4% NCT02480153
- 29.6% vs 31% NCT02480153
- 31.1% vs 30.4% NCT02480153
- 21.5% vs 22% NCT02480153
- 16.5% vs 19% NCT02480153
- 12.5% vs 11.7% NCT02480153
- 8.1% vs 8.7% NCT02480153
- 3.7% vs 3.7% NCT02480153
- 0.7% vs 2% NCT02480153
- adalimumab-ryvk (Simlandi)
- —Not reported
DAS28-CRP remission
- adalimumab-afzb (Abrilada)
- —Not reported
- adalimumab-ryvk (Simlandi)
- —Not reported
HAQ-DI, change
- adalimumab-afzb (Abrilada)
- -0.7 vs -0.7vs Adalimumab-EUNCT02480153
11 other results
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.6 vs -0.6 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.4 vs -0.5 NCT02480153
- -0.3 vs -0.4 NCT02480153
- -0.3 vs -0.3 NCT02480153
- adalimumab-ryvk (Simlandi)
- —Not reported
Modified Sharp score, change
- adalimumab-afzb (Abrilada)
- —Not reported
- adalimumab-ryvk (Simlandi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-ryvk (Simlandi): no structured comparison results are available for Rheumatoid Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-afzb (Abrilada): 2 of 4 rows · adalimumab-ryvk (Simlandi): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-afzb (Abrilada) |
|---|---|
| Dropout rate | —Period 1: PF-06410293a NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 |
| Discontinued due to AEs | —Period 1: PF-06410293a NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 |
| Serious AEs | 4%Period 1: PF-06410293a NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results1.4%Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 3.5%Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.4% NCT04230213 · Phase 3 |
| Most frequent reported AEs | a viral upper respiratory tract infection 7.1% rheumatoid arthritis 1.7% nasopharyngitis 0% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more resultsviral upper respiratory tract infection 5.3% rheumatoid arthritis 1.4% nasopharyngitis 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 nasopharyngitis 5% rheumatoid arthritis 4.7% viral upper respiratory tract infection 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-afzb (Abrilada)
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
+ 46 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · adalimumab-ryvk (Simlandi)'s landscape